ClinicalTrials.gg
Status unknownNCT02103257Updated Apr 29, 2015

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

A Phase 4 interventional study of Sequential Icotinib Plus Chemotherapy and Icotinib in EGFR Positive Non-small Cell Lung Cancer and Adenocarcinoma, sponsored by Betta Pharmaceuticals Co., Ltd.. Status unknown at 31 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-29.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 77 studies in Adenocarcinoma with a site in China — 33 open to participants now, 42 under way, 12 of them phase 3. Adenocarcinoma · China.

Planned enrollment
26th of 68
192 · median 98
Started
2014
with 3 others
Phase 4
4 of 77
1 open now
Registered
16th of 77
by date
Lead sponsor
4 of 77
Betta Pharmaceuticals Co., Ltd.

Among the 77 studies in Adenocarcinoma with a site in China, this one is the 26th largest by planned enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2014, is one of 4 in phase 4, and was the 16th registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

33 of the 77 studies in Adenocarcinoma with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Adenocarcinoma with a site in China, or all of them as a file.
02

Study summary

This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.

03

Conditions studied

  • EGFR Positive Non-small Cell Lung Cancer
  • Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologic confirmation of lung adenocarcinoma with , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT)
  • Patients must have previously untreated locally advanced or NSCLC
  • EGFR activating mutation (exon 19 deletion, L858R) is required
  • performance status (ECOG PS) score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy or treatment with gefitinib, erlotinib, or other drugs that target EGFR
  • Patients with wild-type EGFR
  • Any other agents are not permitted
  • Any evidence of interstitial lung disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    Sequential icotinib plus chemotherapy

    Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.

    Drug: Sequential Icotinib Plus Chemotherapy

  • Active comparator
    Icotinib

    Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.

    Drug: Icotinib

Interventions

  • DrugSequential Icotinib Plus Chemotherapy

    Drug page: Pemetrexed

    Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.

    Also known as: ALIMTA, DDP, Comana, BPI-2009

  • Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.

    Also known as: Comana, BPI-2009

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant are known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a participant will be censored at the last date they are known not to be progressed.

    Time frame: 15 months

Secondary outcomes

  1. Overall survival

    Overall Survival is assessed via calculation of the time to death due to any cause. If a participant is known to have died, the time to death is defined as the time from the date of randomization to the date of death. Otherwise, a participant will be censored at the last date they are known to be alive.

    Time frame: 24 months

  2. Objective response rate

    Number of subjects with confirmed objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    Time frame: 15 months

  3. Adverse events

    The number of patients who suffered adverse events, which is graded by NCI CTCAE version 4.0.

    Time frame: 24 months

07

Study locations

1 of 31 sites recruiting
  • First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
    Active, not recruiting
  • Lanzhou military region general hospital
    Lanzhou, Gansu 730050, China
    Active, not recruiting
  • General Hospital of Guangzhou Military Command
    Guangzhou, Guangdong 510010, China
    Active, not recruiting
  • Cancer Hospital of Sun Yat-sen
    Guangzhou, Guangdong 510060, China
    Active, not recruiting
  • First Affiliated Hospital of Guangzhou Medical College
    Guangzhou, Guangdong 510120, China
    Active, not recruiting
  • Jiangmen central hospital
    Jiangmen, Guangdong 529030, China
    Active, not recruiting
  • The university of Hong Kong-Shenzhen Hospital
    Shenzhen, Guangdong 518000, China
    Active, not recruiting
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
    Active, not recruiting
  • Medical Oncology,Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518035, China
    Active, not recruiting
  • Thoracic Surgery,Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518035, China
    Active, not recruiting
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
    Active, not recruiting
  • Guangdong Agribusiness Center Hospital
    Zhanjiang, Guangdong 524009, China
    Active, not recruiting
  • First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
    Active, not recruiting
  • Hainan Provincal Nong Ken Hospital
    Haikou, Hainan 570311, China
    Active, not recruiting
  • Hainan Provincial People's Hospital
    Haikou, Hainan 570311, China
    Active, not recruiting
  • First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Active, not recruiting
  • Medical Oncology,General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
    Active, not recruiting
  • Radiation Oncology,General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
    Active, not recruiting
  • Respiratory medicine,General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
    Active, not recruiting
  • Baoji Central Hospital
    Baoji, Shanxi 721008, China
    Active, not recruiting
  • 3201 Hospital, Hanzhong, Shanxi
    Hanzhong, Shanxi 723000, China
    Active, not recruiting
  • Shaanxi province people's hospital
    Xi'an, Shanxi 710000, China
    Active, not recruiting
  • Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710004, China
    Active, not recruiting
  • Xi'an Chang'an Hospital
    Xi'an, Shanxi 710018, China
    Active, not recruiting
  • Tangdu Hospital,Fourth Military Medical University
    Xi'an, Shanxi 710038, China
    Recruiting
    • Helong Zhang, MD · Contact13709202616
    • Helong Zhang, MD · Principal investigator
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
    Active, not recruiting
  • Shanxi Cancer Hospital
    Xi'an, Shanxi 710061, China
    Active, not recruiting
  • Urumqi General Hospital of Lanzhou Military Region General Hospital
    Urumqi, Xinjiang 830000, China
    Active, not recruiting
  • Xinjiang medical university affiliated tumor hospital
    Urumqi, Xinjiang 830000, China
    Active, not recruiting
  • First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830054, China
    Active, not recruiting
  • Autonome Region Xinjiang Uygur Chinese medicine hospital
    Urumqi, Xinjiang 830099, China
    Active, not recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Mar 2016 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2014
First posted
Apr 3, 2014
Start
Mar 2014
Primary completionEst.
Mar 2016
CompletionEst.
Sep 2017
Last update
Apr 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02103257
Responsible party
Sponsor
First posted
Apr 3, 2014
Start date
Mar 2014
Primary completion
Mar 2016 (estimated)
Completion
Sep 2017 (estimated)
Last update
Apr 29, 2015

Study contacts

Helong Zhang, MD
Contact
13709202616
Helong Zhang, MD
principal investigator · Tang-Du Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion